Enap-HL 20 mg/12,5 mg tablete
Name | Enap-HL 20 mg/12,5 mg tablete |
---|---|
Marketing Authorisation Number | HR-H-353361877 |
Active Substance | enalaprilmaleat hidroklorotiazid |
Composition | jedna tableta sadrži 20 mg enalaprilmaleata, što odgovara 15,29 mg enalaprila i 12,5 mg hidroklorotiazida |
Pharmaceutical Form | tableta |
Manufacturer | Krka d.d., Novo mesto, Novo Mesto, Slovenija |
Marketing Authorisation Holder | Krka - farma d.o.o., Radnička cesta 48, Zagreb, Hrvatska |
Marketing Authorisation Date | 28.06.2016 |
MA Period of Validity | unlimited |
Classification Number | UP/I-530-09/14-02/511 |
Registration Number | 381-12-01/70-16-07 |
Prescription | na recept |
Type of prescription | ponovljivi recept |
Distribution | u ljekarni |
Advertising to general public | zabranjeno |
ATC Code | C09BA02 |
Medicinal product marketed in the Croatia | Da |
SmPC | download |
PL | download |
Packaging
Direct Healthcare Professional Communication
Name | Date | Download |
---|---|---|
Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |